Premium assistance programs lead to fights between insurers, hospitals

Programs which help customers on the Affordable Care Act (ACA) marketplace buy insurance are being criticized by insurers as they pull out of the exchanges.

Kaiser Health News reports these programs have helped thousands of low-income customers purchase coverage. In one example, 21-year-old Mercedes Nimmer of Madison, Wisconsin, received assistance from UnitedWay of Dane County when federal subsidies left her with a $33 monthly premium—a considerable expense for a multiple sclerosis patient who makes $11,000 per year.

“Oh my gosh, this is a big deal for me to get this help,” Nimmer said, noting the insurance is vital to cover her medications. 

Insurers, however, argue these “steering” programs are unfair, as they drive people to marketplace plans with higher reimbursement for providers when they may qualify for Medicaid or Medicare. CMS has said it may punish dialysis centers that engage in those practices, up to and including changing their Medicaid and Medicare eligibility.

But insurers are already going to the courts to take action against groups paying for marketplace premiums. For more, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.